Acute Respiratory InfectionNCT07298967
ORCHARDS-AIR Study
A study testing Nasal swab and Indoor air quality monitor in people with Acute Respiratory Infection and Influenza-like Illness, run by University of Wisconsin, Madison at 1 site in United States.
Trial summary
The purpose of this observational study is to compare the effectiveness of air surveillance and to better understand the relationship between household transmission and viruses detected in the air. Participants will provide nasal swabs and have an air sample surveillance device installed in their home. Read more about this study
- Who is it for?
- Ages 4 years and older
- Conditions the study is for
- Acute Respiratory Infection, Influenza-like Illness
- What is being tested?
- Nasal swab and Indoor air quality monitor
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 422 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Jan 2026to Jun 2027
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Student attends, or is eligible to attend, a school within the Oregon School District (OSD)
- Study has an illness characterized by at least 2 of 6 acute respiratory infection (ARI)/ILI symptoms (nasal discharge, nasal congestion, sneezing, sore throat, cough, fever) and student scores at least 2 points on the Jackson scale
- Live in the same household as eligible student participant
- Any age and gender
- Fluent in English
- Able to provide appropriate consent or assent
Who cannot join
- Household member listed on Wisconsin Department of Corrections Sex Offender Registry
- Illness onset more than 7 days before anticipated time of specimen collection
- Anatomical defect for which nasal specimen collection is contraindicated
- Student participated too recently (<7 days from day 14 during peak influenza / COVID-19 period and <30 days during other times, as determined by a medically-attended surveillance program)
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Wisconsin-Madison
Madison, Wisconsin, 53705
About this study
Official title: ORegon CHild Absenteeism Due to Respiratory Disease Study - Air Surveillance
The purpose of this observational study is to compare the effectiveness of air surveillance and to better understand the relationship between household transmission and viruses detected in the air.
Participants will provide nasal swabs and have an air sample surveillance device installed in their home.
Read the detailed description
The purpose of ORCHARDS-AIR is to utilize air surveillance in participant homes in conjunction with individually collected nasal specimens to assess their concordance and evaluate the significance of airborne detection with household transmission of common respiratory pathogens such as influenza and SARS-CoV-2.
The researchers postulate that households with documented and probable respiratory pathogen transmission will have higher rates of in-home air surveillance detection. Students with more severe illnesses will be absent more often and spend more time at home, potentially leading to absenteeism being associated with greater air surveillance detections and intrahousehold transmission.
- Being tested
- Nasal swab, Indoor air quality monitor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nasal swabDiagnostic test
Participants will use a swab to collect nasal specimens
Indoor air quality monitorDevice
InBio Apollo ambient air sampler to be run in the home for the duration of study participation. Material from the air, like aerosols, dust particles, and other environmental material, are collected on sampler filler material.
| Study group | Role | What they receive |
|---|---|---|
| Students with ARI (acute respiratoy infection) | Experimental | Students with ARI and their household members will provide nasal swabs Receives: Diagnostic Test: Nasal swab; Device: Indoor air quality monitor |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of virus detection
Participants will provide nasal swabs, which will be tested for a panel of viruses.
Measured: Day 0, Day 7, Day 14
Rate of air sampling detection among families with documented transmission
Study team will collect and test air sampler filter for viruses.
Measured: Day 7, Day 14
Rate of air sampling detection among families without documented transmission
Study team will collect and test air sampler filter for viruses.
Measured: Day 7, Day 14
Survey of symptoms - day 0
Qualitative survey of participants' symptoms and related activities.
Measured: Day 0
Survey of symptoms - day 7
Qualitative survey of participants' symptoms and related activities.
Measured: Day 7
Survey of symptoms - day 14
Qualitative survey of participants' symptoms and related activities.
Measured: Day 14
Air sampler use survey
Qualitative survey about participants' use of the air sampler.
Measured: Day 7, Day 14
Secondary outcomes (1)
Number of absences
Participants will self-report whether they were absent from school during the study period.
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2025
- Study start7 Jan 2026
- Primary completionJun 2027 (estimated)
- Study completionJun 2027 (estimated)
Why it stopped: for the summer, continue enrollment this fall
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Respiratory InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 422 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jonathan Temte, MD, PhD, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07298967
- Sponsor's protocol ID
- 2025-1617
- Other IDs
- AS, UWMSN | SMPH | DFMCH Departmen, Protocol Version 12/15/2025
- Status last verified
- Jun 2026
- First submitted
- 19 Dec 2025
- Last updated
- 12 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ORegon CHild Absenteeism Due to Respiratory Disease Study - Air Surveillance
- ClinicalTrials.gov ID
- NCT07298967
- Acronym / sponsor ID
- 2025-1617
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: for the summer, continue enrollment this fall
- Enrolment
- 422 participants (estimated)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Study start
- 7 Jan 2026 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 23 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this observational study is to compare the effectiveness of air surveillance and to better understand the relationship between household transmission and viruses detected in the air.
Participants will provide nasal swabs and have an air sample surveillance device installed in their home.
Detailed description
The purpose of ORCHARDS-AIR is to utilize air surveillance in participant homes in conjunction with individually collected nasal specimens to assess their concordance and evaluate the significance of airborne detection with household transmission of common respiratory pathogens such as influenza and SARS-CoV-2.
The researchers postulate that households with documented and probable respiratory pathogen transmission will have higher rates of in-home air surveillance detection. Students with more severe illnesses will be absent more often and spend more time at home, potentially leading to absenteeism being associated with greater air surveillance detections and intrahousehold transmission.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Students with ARI (acute respiratoy infection) | Experimental | Diagnostic Test: Nasal swab, Device: Indoor air quality monitorStudents with ARI and their household members will provide nasal swabs |
Who may qualify
- Ages
- 4 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Student attends, or is eligible to attend, a school within the Oregon School District (OSD)
- Study has an illness characterized by at least 2 of 6 acute respiratory infection (ARI)/ILI symptoms (nasal discharge, nasal congestion, sneezing, sore throat, cough, fever) and student scores at least 2 points on the Jackson scale
- Live in the same household as eligible student participant
- Any age and gender
- Fluent in English
Key exclusion criteria (4 listed)
- Household member listed on Wisconsin Department of Corrections Sex Offender Registry
- Illness onset more than 7 days before anticipated time of specimen collection
- Anatomical defect for which nasal specimen collection is contraindicated
- Student participated too recently (<7 days from day 14 during peak influenza / COVID-19 period and <30 days during other times, as determined by a medically-attended surveillance program)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nasal swabParticipants will use a swab to collect nasal specimens | Diagnostic test | Students with ARI (acute respiratoy infection) |
| Indoor air quality monitorInBio Apollo ambient air sampler to be run in the home for the duration of study participation. Material from the air, like aerosols, dust particles, and other environmental material, are collected on sampler filler material. | Device | Students with ARI (acute respiratoy infection) |
Primary outcome
Rate of virus detection
Time frame: Day 0, Day 7, Day 14
Participants will provide nasal swabs, which will be tested for a panel of viruses.
Rate of air sampling detection among families with documented transmission
Time frame: Day 7, Day 14
Study team will collect and test air sampler filter for viruses.
Rate of air sampling detection among families without documented transmission
Time frame: Day 7, Day 14
Study team will collect and test air sampler filter for viruses.
Survey of symptoms - day 0
Time frame: Day 0
Qualitative survey of participants' symptoms and related activities.
Survey of symptoms - day 7
Time frame: Day 7
Qualitative survey of participants' symptoms and related activities.
Survey of symptoms - day 14
Time frame: Day 14
Qualitative survey of participants' symptoms and related activities.
Air sampler use survey
Time frame: Day 7, Day 14
Qualitative survey about participants' use of the air sampler.
1 secondary outcome
Number of absences
Time frame: 14 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
- Individual participant dataSharing planned: Yes
Related trials for Acute Respiratory Infection
Not yet recruiting
Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections
Bronchitis, Acute, Community-acquired Pneumonia
Not yet recruitingPhase 2/3
Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza
Influenza, Human
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 4
A Single Dose of Intravenous Penicillin as an Adjunct to Oral Penicillin in the Treatment of Acute Tonsillitis, Peritonsillar Phlegmon, and Peritonsillar Abscess
Acute Tonsillitis, Peritonsillar Abscess
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jonathan Temte, MD, PhD principal investigator
University of Wisconsin, Madison
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nasal swab and Indoor air quality monitor in people with Acute Respiratory Infection and Influenza-like Illness, run by University of Wisconsin, Madison at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of virus detection (time frame: Day 0, Day 7, Day 14). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.